Mydecine Reports Positive Preclinical Results on the MYCO-006 Series of its Short-Acting MDMA Analogues
24 avr. 2023 11h16 HE
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, April 24, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering...
Mydecine Innovations Group Provides Corporate Update
03 avr. 2023 06h00 HE
|
Mydecine Innovations Group Inc.
VANCOUVER, British Columbia, April 03, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering...
Mydecine Reports Financial Results for the Year Ended December 2022
31 mars 2023 20h21 HE
|
Mydecine Innovations Group Inc.
DENVER, March 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of...
Mydecine Announces Debt Settlements
06 mars 2023 07h00 HE
|
Mydecine Innovations Group Inc.
DENVER, March 06, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of...
Mydecine Innovations Group Closes Sale of Its Wholly-Owned Subsidiary, Mindleap Health Inc.
12 déc. 2022 11h39 HE
|
Mydecine Innovations Group Inc.
DENVER, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of...
Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
21 nov. 2022 12h01 HE
|
Mydecine Innovations Group Inc.
DENVER, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of...
Mydecine Reports Financial Results for the Third Quarter of Fiscal Year 2022
14 nov. 2022 17h44 HE
|
Mydecine Innovations Group Inc.
DENVER, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"), a biotechnology company aiming to transform the treatment of...
Mydecine Innovations Group Signs a Letter of Intent to Sell its Wholly-Owned Subsidiary, Mindleap Health Inc.
01 sept. 2022 10h00 HE
|
Mydecine Innovations Group Inc.
DENVER, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of...
Mydecine Innovations Group Announces Common Share Subscription Agreement
29 août 2022 16h00 HE
|
Mydecine Innovations Group Inc.
DENVER, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of...
Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors
19 août 2022 11h06 HE
|
Mydecine Innovations Group Inc.
DENVER, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of...